Interstitial lung disease develops as a sequelae of several autoimmune disorders, yet information regarding its immunopathogenesis, clinical progression, and effective treatment remains scarce. Recent developments in our scientific understanding of fibrogenesis, the biology of circulating fibrocytes, and potential biomarkers will be reviewed with the aim of catalyzing new avenues for investigation and approaches for treatment.
Upon completion of this session, participants should be able to:
- identify current concepts of the immune pathogenesis of interstitial lung diseases
- describe the role of fibrocytes in systemic fibroses and their biomarker potential
- analyze the adaptive immune mechanisms that may govern fibrogenesis
|Moderators:||Richard J. Bucala, MD, PhD, Yale University School of Med and Carol A. Feghali-Bostwick, PhD, University of Pittsburgh|
To see other sessions for this day, use the date buttons to the left.